<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00860379</url>
  </required_header>
  <id_info>
    <org_study_id>2007-P-001176</org_study_id>
    <nct_id>NCT00860379</nct_id>
  </id_info>
  <brief_title>The Effect of Selenium Supplementation Among Pediatric Patients With Burns</brief_title>
  <official_title>The Effect of Selenium Supplementation Among Pediatric Patients With Burns</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shriners Hospitals for Children</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shriners Hospitals for Children</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The selenium status of children with major burns is suboptimal which may increase the&#xD;
      incidence of infection. Se requirements during critical illness are not known. Results from&#xD;
      this investigation may provide a tool for recommending Se supplements during burn injury.&#xD;
&#xD;
      The hypothesis of this research is that Se supplementation will restore the depressed Se&#xD;
      status among children with burn injuries. The secondary hypothesis is that Se status is&#xD;
      related to the incidence of infection among pediatric patients with burns.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Title: The effect of selenium supplementation among pediatric patients with burns&#xD;
&#xD;
      Primary Investigator: Maggie L. Dylewski, PhD, RD&#xD;
&#xD;
      Co-investigators: RL. Sheridan, MD; C Ryan, MD; K Prelack, PhD,RD; M Lydon, RN; J Weber, RN,&#xD;
      BSN, CIC&#xD;
&#xD;
      Approved by: FDA (IND # 78963), Partners IRB (#2007-P-001176).&#xD;
&#xD;
      Funding: private grant from the Boston Burn Foundation&#xD;
&#xD;
      Background Information: Selenium, an essential dietary nutrient, is a component of&#xD;
      glutathione peroxidase (an antioxidant) and thioredoxin reductase, an enzyme that regulates&#xD;
      cytokine expression and thus plays a role in the immune system. Previous studies among adult&#xD;
      burn patients showed that IV selenium supplementation was related to decreased infection and&#xD;
      mortality. Please refer to the study protocol for further details.&#xD;
&#xD;
      Previous Research: We previously showed that children with burns (n = 20) &gt; 20% TBSA had low&#xD;
      plasma selenium values compared to reference data of healthy American children. Results from&#xD;
      this study also found a significant relationship between plasma selenium and incidence of&#xD;
      infections.&#xD;
&#xD;
      Study Design: Randomized, double-blind, placebo-controlled clinical trial&#xD;
&#xD;
      Specific Aims:&#xD;
&#xD;
        1. to determine the impact of supplemental selenium on plasma selenium, glutathione&#xD;
           peroxidase activity, and urine selenium among pediatric patients with burns &gt;20% total&#xD;
           body surface area (TBSA) burn.&#xD;
&#xD;
        2. to determine the association between selenium supplementation, biomarkers of Se status&#xD;
           and indicators of stress and infection.&#xD;
&#xD;
      Subjects: N = 75 pediatric patients with burns.&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        -  Between 1 and 18 years of age admitted to Shriners Burns Hospital&#xD;
&#xD;
        -  TBSA burn of &gt; 20%&#xD;
&#xD;
        -  Existing IV catheter&#xD;
&#xD;
        -  Enrolled into study within 3 weeks of burn injury&#xD;
&#xD;
      Treatment:&#xD;
&#xD;
      All subjects will be randomized into 1 of 3 groups and receive the treatment for 8 weeks,&#xD;
      until 95% wound closure, or until central venous catheter access is discontinued.&#xD;
&#xD;
        1. Placebo (IV 0.9% sodium chloride)&#xD;
&#xD;
        2. 2 mcg/kg/day IV Selenium&#xD;
&#xD;
        3. 4 mcg/kg/day IV Selenium&#xD;
&#xD;
      Biological sample collection:&#xD;
&#xD;
        -  4 mL or 8 mL (8 every other week) of plasma once a week&#xD;
&#xD;
        -  24-hour urine collection once a week&#xD;
&#xD;
      Sample analyses:&#xD;
&#xD;
        -  Samples will be frozen until analyses&#xD;
&#xD;
        -  Samples will be sent to the outside lab for analyses.&#xD;
&#xD;
        -  Plasma will also be sent to Massachusetts General Hospital every other week for plasma&#xD;
           selenium analysis (to assess for toxicity)&#xD;
&#xD;
      Primary outcome measures:&#xD;
&#xD;
        -  Plasma selenium&#xD;
&#xD;
        -  Plasma glutathione peroxidase&#xD;
&#xD;
        -  Urine selenium&#xD;
&#xD;
      Secondary outcome measures:&#xD;
&#xD;
      â€¢ occurrence of pneumonia or infection (bacterial or fungal) in the wound, blood, or urine&#xD;
&#xD;
      Risks:&#xD;
&#xD;
        -  Supplement doses were determined using data from previous studies, current recommended&#xD;
           dietary allowance (RDA) and upper tolerable limits, American Society for Parenteral and&#xD;
           Enteral Nutrition (ASPEN) guidelines for parenteral selenium, and dietary data recorded&#xD;
           from our previous study. According to reference weights (NHANES III) supplement doses do&#xD;
           not exceed the upper tolerable limits for children.&#xD;
&#xD;
        -  Selenium toxicity is rare. However plasma will be assessed every other week for selenium&#xD;
           levels.&#xD;
&#xD;
      Monitoring and Quality Assurance:&#xD;
&#xD;
        -  All subjects will be monitored for any treatment-related adverse events for 2 weeks&#xD;
           following discontinuation of the study therapy&#xD;
&#xD;
        -  Any adverse events will be reported to the Partners Human Research Committee and the FDA&#xD;
           per the guidelines.&#xD;
&#xD;
      An independent Data Safety Monitoring Board, consisting of 4 knowledgeable staff members,&#xD;
      will meet 2 times per year to monitor the data for safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to a shift in primary responsibilities, the PI was not longer able to enroll subjects.&#xD;
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Selenium</measure>
    <time_frame>Average plasma selenium calculated over 8 weeks, assessed weekly.</time_frame>
    <description>plasma selenium of all subjects was assessed</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Burns</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selenium1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive 2 ug/kg of IV selenium per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selenium2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will receive 4 ug/kg of IV selenium per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selenium1</intervention_name>
    <description>2 ug/kg</description>
    <arm_group_label>Selenium1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Selenium2</intervention_name>
    <description>4 ug/kg</description>
    <arm_group_label>Selenium2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>IV saline as placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Between 1 and 18 years of age admitted to Shriners Burns Hospital&#xD;
&#xD;
          -  TBSA burn of &gt; 20%&#xD;
&#xD;
          -  Existing IV catheter&#xD;
&#xD;
          -  Enrolled into study within 3 weeks of burn injury&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt; 1 year or &gt; 18 years of age&#xD;
&#xD;
          -  &lt; 20% TBSA burn&#xD;
&#xD;
          -  No existing IV catheter&#xD;
&#xD;
          -  Pre-existing or acute renal disease (creatine &gt; 1.5 mg/dl)&#xD;
&#xD;
          -  Pre-existing or acute liver disease (bilirubin &gt; 3)&#xD;
&#xD;
          -  Pre-existing or acute thyroid disorders&#xD;
&#xD;
          -  Cancer&#xD;
&#xD;
          -  AIDS&#xD;
&#xD;
          -  Pregnancy (as determined by routine admission labs)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maggie L Dylewski, PhD,RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shriners Hospitals for Children</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shriners Hospitals for Children</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>March 11, 2009</study_first_submitted>
  <study_first_submitted_qc>March 11, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2009</study_first_posted>
  <results_first_submitted>May 25, 2021</results_first_submitted>
  <results_first_submitted_qc>July 9, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 29, 2021</results_first_posted>
  <last_update_submitted>July 9, 2021</last_update_submitted>
  <last_update_submitted_qc>July 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shriners Hospitals for Children</investigator_affiliation>
    <investigator_full_name>Maggie Dylewski</investigator_full_name>
    <investigator_title>PhD,RD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 4, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT00860379/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo&#xD;
Placebo: IV saline as placebo</description>
        </group>
        <group group_id="P2">
          <title>Selenium 2 ug/kg</title>
          <description>Subject will receive 2 ug/kg of IV selenium per day&#xD;
Selenium1: 2 ug/kg</description>
        </group>
        <group group_id="P3">
          <title>Selenium 4 ug/kg</title>
          <description>Subject will receive 4 ug/kg of IV selenium per day&#xD;
Selenium2: 4 ug/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo&#xD;
Placebo: IV saline as placebo</description>
        </group>
        <group group_id="B2">
          <title>Selenium1</title>
          <description>Subject will receive 2 ug/kg of IV selenium per day&#xD;
Selenium1: 2 ug/kg</description>
        </group>
        <group group_id="B3">
          <title>Selenium2</title>
          <description>Subject will receive 4 ug/kg of IV selenium per day&#xD;
Selenium2: 4 ug/kg</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.8" spread="0.66"/>
                    <measurement group_id="B2" value="4.3" spread="4.0"/>
                    <measurement group_id="B3" value="6.3" spread="5.39"/>
                    <measurement group_id="B4" value="4.74" spread="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Body Surface Area (TBSA) burn injury</title>
          <units>% of body surface area burn</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.5" spread="9.29"/>
                    <measurement group_id="B2" value="42.8" spread="23.16"/>
                    <measurement group_id="B3" value="49.3" spread="26.25"/>
                    <measurement group_id="B4" value="46.25" spread="19.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Selenium</title>
        <description>plasma selenium of all subjects was assessed</description>
        <time_frame>Average plasma selenium calculated over 8 weeks, assessed weekly.</time_frame>
        <population>pediatric burn patients</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo&#xD;
Placebo: IV saline as placebo</description>
          </group>
          <group group_id="O2">
            <title>Selenium1</title>
            <description>Subject will receive 2 ug/kg of IV selenium per day&#xD;
Selenium1: 2 ug/kg</description>
          </group>
          <group group_id="O3">
            <title>Selenium2</title>
            <description>Subject will receive 4 ug/kg of IV selenium per day&#xD;
Selenium2: 4 ug/kg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Selenium</title>
          <description>plasma selenium of all subjects was assessed</description>
          <population>pediatric burn patients</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45" spread="5.2"/>
                    <measurement group_id="O2" value="46" spread="19.1"/>
                    <measurement group_id="O3" value="52.9" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were monitored for adverse events between baseline and 2 weeks following discontinuation of the study therapy, up to 10 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo&#xD;
Placebo: IV saline as placebo</description>
        </group>
        <group group_id="E2">
          <title>Selenium1</title>
          <description>Subject will receive 2 ug/kg of IV selenium per day&#xD;
Selenium1: 2 ug/kg</description>
        </group>
        <group group_id="E3">
          <title>Selenium2</title>
          <description>Subject will receive 4 ug/kg of IV selenium per day&#xD;
Selenium2: 4 ug/kg</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Maggie Dylewski Begis</name_or_title>
      <organization>Shriners Hospitlas for Children</organization>
      <phone>617-872-8567</phone>
      <email>mdylewski@shrinenet.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

